Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab subcutaneous versus intravenous pharmacokinetic study in resected adjuvant melanoma
2021-003208-42Phase 3Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Part 1 primary endpoint. Started Mar 2022; status: suspended.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2021-003208-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003208-42.